Novo Nordisk has requested that the FDA prohibit compounding pharmacies from producing unapproved versions of its popular weight loss and diabetes drugs, Wegovy and Ozempic, CNBC reported Oct. 23.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
